Biosimilars in Argentina: ANMAT Approval and Market Growth Analysis 2025

Key Takeaways

• Market scale: ANMAT has approved over 67 biosimilars spanning monoclonal antibodies, insulins, growth hormones, and anticoagulants as of April 2025 (Gerarduzzi, 2025).
• Cost impact: TNF inhibitor biosimilars deliver 39–88% price reductions versus originator biologics, directly improving treatment accessibility (Global Health Economics 2025).
• Medical endorsement: Seven Argentine medical associations support biosimilar integration across rheumatology, gastroenterology, and dermatology specialties.
• Regulatory evolution: Disposition 1741/2025 introduced detailed comparability guidelines in March 2025, refining ANMAT's biosimilar framework.
• Clinical reach: Approved biosimilars address autoimmune, dermatological, gastrointestinal, rheumatic, and endocrine indications.

What Are Biosimilars and How Do They Differ from Generics?

Biosimilars are biological products highly similar to an already licensed reference biologic (also called reference medicinal products or RPs). Unlike traditional generic drugs, which are chemically identical copies of small-molecule medicines, biosimilars are manufactured in living cells. This biological origin means they can demonstrate high similarity—but not identical structure—to their reference products.

The WHO Guidelines on Evaluation of Biosimilars establish that these products must show no clinically meaningful differences from the reference in terms of quality, safety, or efficacy. In Argentina, ANMAT regulates biosimilars under Disposition 7729/2011, which aligns with EMA and WHO standards.

The key distinction matters for patients and payers. Small-molecule generics typically enter at 80% discounts. Biosimilars, due to their complex manufacturing and clinical comparability requirements, achieve price reductions of 15% to 88% depending on market maturity and competition intensity.

What Is ANMAT's Role in Biosimilar Regulation?

ANMAT serves as Argentina's national regulatory authority for medicines, food, and medical devices. Established by Decree 1490/1992, the agency operates through specialized institutes including INAME (National Institute of Medicines), which handles pharmaceutical evaluation.

The agency's biosimilar framework rests on two key regulations:

• Disposition 7729/2011: Establishes requirements for biosimilar registration, mandating comparability exercises that demonstrate equivalence to reference biologics.
• Disposition 1741/2025: Published March 14, 2025, this update introduces detailed comparability guidelines aligned with international standards. The new framework allows analytical and functional comparability data to potentially reduce clinical study requirements where high similarity is proven at the quality level.

ANMAT's approach emphasizes the "totality of evidence"—weighing analytical, nonclinical, and clinical data together rather than requiring each element to identically match reference products.

How Many Biosimilars Has ANMAT Approved?

As of April 2025, ANMAT has authorized over 67 biosimilar products. This portfolio spans multiple therapeutic classes:

ANMAT-Approved Biosimilars by Therapeutic Class (selected examples)

Therapeutic Class	Example Products	Key Indications
Monoclonal antibodies	Rituximab (Novex), Bevacizumab (Bevax), Trastuzumab	Lymphoma, colorectal cancer, breast cancer
TNF inhibitors	Adalimumab, Infliximab, Etanercept biosimilars	Rheumatoid arthritis, Crohn's disease, psoriasis
Insulins	Insulin glargine, Insulin lispro biosimilars	Type 1 and Type 2 diabetes
Growth hormones	Somatropin (Omnitrope, HHT, Zomacton)	Growth hormone deficiency, Turner syndrome
Anticoagulants	Enoxaparin sodium (Enoxaparin FADA, Heparinox)	Venous thromboembolism prevention
G-CSF	Filgrastim (Filgrastim Duncan, Neupogen)	Neutropenia, febrile neutropenia

The 67+ approved products position Argentina among the leading biosimilar markets in Latin America, alongside Brazil and Mexico.

What Cost Savings Do Biosimilars Deliver in Argentina?

Price competition between biosimilars and originator biologics generates substantial cost reductions in Argentina. A 2025 cross-national analysis published in Global Health Economics and Sustainability found that Argentine biosimilars achieved price reductions ranging from 39% to 88% versus reference products for TNF inhibitors (Gerarduzzi, 2025).

Specific findings include:

• Adalimumab biosimilars: Price reductions at the higher end of the 39–88% range
• Infliximab biosimilars: Varying discounts; one approved biosimilar showed 14.4% reduction while competitive dynamics have driven larger discounts
• Etanercept biosimilars: Significant discounts improving access for rheumatoid arthritis and psoriasis patients

These cost savings have direct healthcare system impact. A 2020 study by ISALUD University's CETSA (Center for Health Technology Assessment) found accumulated savings of $65.7 million since Argentina's first biosimilar approval in 2014. Over 35,000 patients received biosimilar therapies, with access expanding as prices decreased.

Which Medical Associations Support Biosimilar Use?

Seven medical associations in Argentina actively endorse biosimilar integration into clinical practice. This professional support spans key therapeutic areas:

• Rheumatology: Recognition of TNF inhibitor biosimilars for rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
• Gastroenterology: Support for infliximab and adalimumab biosimilars in inflammatory bowel disease (Crohn's disease, ulcerative colitis)
• Dermatology: Endorsement for psoriasis and psoriatic arthritis indications
• Oncology: Acceptance of rituximab and bevacizumab biosimilars for lymphoma and solid tumors
• Endocrinology: Support for insulin and growth hormone biosimilars

These endorsements strengthen physician confidence in biosimilar safety and efficacy profiles. However, the associations generally advocate caution regarding automatic substitution and interchangeability, favoring physician-supervised product changes with proper patient monitoring.

What Therapeutic Areas Do Biosimilars Cover?

ANMAT-approved biosimilars address a broad spectrum of disease areas reflecting the multi-system applications of biological therapies:

• Autoimmune diseases: Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus
• Dermatological conditions: Psoriasis, hidradenitis suppurativa
• Gastrointestinal diseases: Crohn's disease, ulcerative colitis
• Rheumatic diseases: Juvenile idiopathic arthritis, various inflammatory arthritides
• Endocrine disorders: Type 1 and Type 2 diabetes (insulins), growth hormone deficiency
• Oncology: Non-Hodgkin lymphoma, colorectal cancer, breast cancer
• Hematology: Neutropenia, febrile neutropenia

This breadth reflects both the TNF-mediated inflammatory pathways common across many conditions and the specific mechanisms of non-TNF biologics like rituximab (CD20 targeting) and bevacizumab (VEGF inhibition).

How Does ANMAT's Pathway Compare to Other LATAM Regulators?

Argentina's biosimilar regulatory approach shows both alignment with and divergence from other Latin American agencies:

Comparison of LATAM Biosimilar Regulatory Approaches

Aspect	Argentina (ANMAT)	Brazil (ANVISA)	Mexico (COFEPRIS)
Primary regulation	Disposition 7729/2011; 1741/2025	RDC 55/2010; RDC 305/2019	NOM-257-SSA1-2014
Comparability requirements	Analytical, nonclinical, clinical	Quality, safety, efficacy data	Similar to WHO guidelines
Interchangeability guidance	Limited specific guidance	Under development	Automatic substitution not defined
Approved products (2025)	67+	Substantial portfolio	Growing approvals

ANMAT's March 2025 comparability guideline update positions the agency's framework closer to EMA standards than some neighboring jurisdictions. The emphasis on analytical comparability potentially reducing clinical study requirements follows the scientific consensus that high structural and functional similarity at the quality level can streamline clinical development. See also our coverage of ANVISA and COFEPRIS regulatory frameworks.

What Is the Future Outlook for Argentina's Biosimilar Market?

Regional harmonization initiatives may accelerate biosimilar approvals across Latin America. Coordination between ANMAT, Brazil's ANVISA, and Mexico's COFEPRIS could reduce duplicative regulatory work and facilitate cross-border commerce. The WHO Prequalification Programme's pilot for biotherapeutics provides additional reference standards that ANMAT and other LATAM agencies increasingly consult.

Domestically, Argentina's biosimilar industry continues expanding. Local manufacturer mAbxience (part of Grupo Insud) operates a state-of-the-art monoclonal antibody facility producing rituximab and bevacizumab biosimilars for domestic use and export to over 50 countries including EU member states. The 2025 launch of pembrolizumab biosimilar Pembrox by Laboratorio Elea marked the world's first biosimilar competition for Keytruda, demonstrating Argentina's capacity for innovative biosimilar development.

Policy developments to monitor include:

• Potential implementation of biosimilar-preferential reimbursement policies
• Pharmacovigilance system enhancements for post-market biosimilar monitoring
• Clearer guidance on interchangeability and automatic substitution
• Patent policy changes affecting biosimilar market entry timing

Frequently Asked Questions

Primary Sources

1. Gerarduzzi DA, et al. (2025). "Biosimilars in Argentina: Market and regulatory status." Global Health Economics and Sustainability. DOI: 10.36922/GHES025210041.
2. ANMAT (2025). "ANMAT dispuso una Guía de Comparabilidad para el desarrollo de productos Biosimilares." Argentina.gob.ar, March 17, 2025.
3. ANMAT. "Inscripciones en el Registro de Especialidades Medicinales." Argentina.gob.ar.
4. WHO (2025). "Guidelines on Evaluation of Biosimilars." World Health Organization. who.int.
5. Sandorff E, et al. (2015). "Payer and physician evidence and discount requirements for biosimilars in three Latin American countries." GaBI Journal. DOI: 10.5639/gabij.2015.0401.005.
6. Machado FL, et al. (2024). "A cross-national comparison of biosimilars pricing in Argentina, Australia, Brazil, and Italy." Therapeutic Innovation & Regulatory Science 58:549-556. DOI: 10.1007/s43441-024-00623-8.
7. GaBI Online. "Biosimilars approved in Argentina." gabionline.net.